Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai has entered into a Japan co-promotion agreement with Novartis Pharma for three Novartis Pharma therapies for chronic obstructive pulmonary disease (COPD).
Subscribe to our email newsletter
The therapies include Onbrez Inhalation Capsules 150 mcg (indacaterol maleate) and the investigational drugs NVA237 (glycopyrronium bromide) and QVA149 (fixed-dose combination of indacaterol maleate and glycopyrronium bromide).
NVA237and QVA149are currently in Phase III development.
As per the deal, both the companies will co-promote Onbrez and commence co-promotion of NVA237 and QVA149 once they are launched.
Novartis Pharma intends to maximize the value of Onbrez, as well as NVA237 and QVA149.
Eisai aims to improve its product portfolio in the area of internal medicine.